Call toll-free 800.328.1267

Insights AI

The market’s most important stocks, simplified

Pfizer Inc. is expected to report declines in Q1 2025 earnings, with EPS projected to drop from $0.82 to $0.68 and revenue anticipated to fall from $14.88 billion to $14.09 billion year-over-year. Analysts have shown mixed sentiment, with UBS and Goldman Sachs downgrading their ratings to Neutral and lowering price targets to $24 and $25, respectively, while Guggenheim maintained a Buy rating with a $33 target. Financial metrics, including net margin (2.31%), return on equity (0.45%), and return on assets (0.19%), remain below industry averages, signaling challenges in profitability and efficiency. However, Pfizer has achieved 21.93% revenue growth over the last three months. Strategically, Pfizer is advancing its oncology portfolio through a collaboration with Guardant Health and has reported results from its Phase 3 TALAPRO-2 study, though details remain undisclosed. While the company faces near-term financial pressures and mixed analyst sentiment, its recent revenue growth and strategic initiatives highlight areas of potential long-term opportunity.
Source content provided by Benzinga.
This content was created in whole or in part using Generative Artificial Intelligence (AI). Please read the disclosures found at the end of this content for more information.

Ready to make your move?

You’ve seen the news. It’s time to set your strategy. The TradeStation ecosystem is designed to execute your trades no matter how unique or complex. Set your strategy in motion with the advanced tools and brokerage services built specifically for those who are born to trade

Recent news for PFE

News in this section is provided by Benzinga and is written entirely by Benzinga authors. Articles are presented as they were provided by Benzinga, and do not represent the opinions of TradeStation or its employees.

By clicking one of the links below, you are leaving TradeStation.com.

Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock

Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money."

Mark Cuban Slams Charlie Kirk Over Drug Price Debate, Says PBMs — Not Big Pharma — Are The Real Villains: 'For Your Company…Ask Your PBM For A List Of Claims'

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk's stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma.

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket

What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.

About PFE

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and ... Read more

Ways to trade options* on PFE

Bearish Option Strategy: Put Spread

Traders buy a put option near the money and sell another at a lower strike. This strategy can leverage a price drop with limited capital at risk.

Learn more

  • 1
  • 2
  • 3

Insights AI filters through the noise to uncover meaningful data that natural-born traders can use to find new trading opportunities. Our AI model distills complex market news and data into accessible, actionable intelligence. Stay informed of market moves with curated trading intelligence and platform tips delivered directly to you.

Market Insights, Insights AI, and all related pages and content are hosted by TradeStation Group, Inc.

The symbols selected include stocks that meet a specific set of criteria: the 50 most active stocks based on 21-day options volume. ETFs and meme stocks are not included.

This Content was created in whole or in part using Generative Artificial Intelligence (AI). While efforts have been made to ensure accuracy, the Content is generated autonomously by AI algorithms and it may contain errors or inaccuracies. Users are advised to critically evaluate the information presented.

This Content is for educational and informational purposes only. Any symbols or trading strategies discussed are for demonstration purposes only and are not research or recommendations.

TradeStation Group, Inc. (“TradeStation”) pays third parties for the data and other information included on this page (the “Content”). The Content is derived from news and other information feeds provided by Accretive Capital LLC d/b/a Benzinga (“Benzinga”) and market activity. Benzinga is not affiliated with TradeStation. TradeStation makes the Content available for informational purposes only. The Content should not be considered an offer or solicitation tobuy, sell, or hold any investment/security. The Content is believed to be from reliable sources; however, TradeStation does not verify all of the information included in the Content for accuracy or completeness. TradeStation does not endorse any third-party content, and any views or opinions expressed in the Content do not necessarily represent the views and opinions of TradeStation. Any goods or services offered by Benzinga are not sponsored, endorsed, sold, or promoted by TradeStation, and TradeStation makes no representation regarding any such goods or services.

TradeStation does not endorse or adopt the Content, and makes no guarantees that the Content is accurate, complete, or timely. TradeStation assumes no responsibility for the accuracy, completeness, updates, changes, or timeliness of the Content. TradeStation does not provide investment, tax or legal advice. Any recommendation, opinion or advice regarding securities or markets contained in the Content does not reflect the views of TradeStation. TradeStation assumes no responsibility for any fact, recommendation, opinion or advice contained in the Content and expressly disclaims any responsibility for any decisions based upon any such Content.

Any decisions you may make to buy, sell or hold a security or other investment based on the Content or other third-party information will be entirely your own and not in any way deemed to be endorsed, influenced by or attributed to TradeStation. It is understood that, without exception, any order based on the Content that is placed with TradeStation for execution should be considered by you to be an unrecommended and unsolicited order. TradeStation will treat all such orders as unsolicited.

*Options trading is not suitable for all investors. Your TradeStation Securities’ account application to trade options will be considered and approved or disapproved based on all relevant factors, including your trading experience. See www.TradeStation.com/DisclosureOptions. Visit www.TradeStation.com/Pricing for full detailson the costs and fees associated with options.